Département de médecine

Appartenances mineures

Service d'immunologie, Département de pédiatrie

Études médicales

Interne des Hôpitaux d'ILE DE FRANCE (M.D.), 1987

Études médicales postdoctorales

Docteur en médecine - Spécialité rhumatologie, 1994
Faculté de médecine Pitié-Salpétrière
Université Pierre et Marie Curie, Paris VI, France

Études postdoctorales

2002, Université de Paris XI (Paris-Sud)

Doctorat

Sciences, 1997, Université Paris VII, France

Maîtrise

DEA, 1993, Université de Paris VII, France
Biochimie, 1989, Université Paris VII, France<//font>

Thèmes de recherche

• Physiologie osseuse.
• Pathologies osseuses.
• Ostéoclaste.
• Myélome.
• Résorption osseuse.
• Immunocytochimie.
• Biologie cellulaire.
• Apoptose.

Axe et thème porteur de recherche

Inflammation - Douleur

Commandites de recherche en cours

Une étude de cohorte réalisée dans le cadre d'une pratique réelle chez des femmes postménauposées atteintes d'ostéoporose traitées avec Aclasta ou un biphosphonate oral.

Chercheure principale : Roux S

Organisme commanditaire :
Novartis Pharma Canada inc.

Supervision d'étudiants - 5 dernières années

(2e, 3e cycles et stagiaires postdoctoraux)

Boulay-Jean, Stéphanie

Programme : Pharmacologie

Diplôme : M. Sc. en cours

Titre de la recherche : NFATc1 activation in pagetic osteoclasts.

Bourse : S/O

Directrice : Roux S

McManus, Stephen

Programme : Immunologie

Diplôme : Ph. D. en cours

Titre de la recherche : RANKL signaling pathway and p62-associated kinases in the activation of Pagetic human osteoclasts in vitro.

Bourse : S/O

Directrice : Roux S

Supervision terminée

Couture, Julie

Programme : Immunologie

Diplôme : Ph. D. obtenu en 2009

Titre de la recherche : Role of p62 P392L Mutation in Pagetic Osteoclasts.

Bourse : S/O

Directrice : Roux S

Fong, David

Programme : Génie chimique

Diplôme : M. Sc. obtenue en 2010

Titre de la recherche : Le comportement des ostéoclastes humains au contact des biomatériaux.

Bourse : Bourse institutionnelle de la Faculté de génie

Directrice : Roux S

McManus, Stephen

Programme : Immunologie

Diplôme : M. Sc. obtenue en 2010

Titre de la recherche : Modulation of Tumor Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL) Receptors in a Human Osteoclast Model In Vitro Present Position.

Bourse : S/O

Directrice : Roux S

Publications d'articles (2009-...)

Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report.
Bissonnette L, April PM, Dumais R, Boire G, Roux S.
Bone. 2013 Oct;56(2):406-9. doi: 10.1016/j.bone.2013.07.012. Epub 2013 Jul 17. PMID: 23871749

Priming primary care physicians to treat osteoporosis after a fragility fracture: an integrated multidisciplinary approach.
Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G.
J Rheumatol. 2013 May;40(5):703-11. doi: 10.3899/jrheum.120908. Epub 2013 Mar 15. PMID:23504379

Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
Fong D, Bisson M, Laberge G, McManus S, Grenier G, Faucheux N, Roux S.
Cell Signal. 2013 Apr;25(4):717-28. doi: 10.1016/j.cellsig.2012.12.003. Epub 2013 Jan 8. PMID:23313128

Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-κB in human osteoclasts.
Chamoux E, McManus S, Laberge G, Bisson M, Roux S.
Biochim Biophys Acta. 2012 Dec 22;1832(3):475-484. doi: 10.1016/j.bbadis.2012.12.008. [Epub ahead of print] PMID: 23266528

Prostaglandin D2 induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway.
Yue L, Durand M, Lebeau Jacob MC, Hogan P, McManus S, Roux S, de Brum-Fernandes AJ.
Bone. 2012 Sep;51(3):338-46. doi: 10.1016/j.bone.2012.06.003. Epub 2012 Jun 12. PMID: 22705147

The adaptor protein p62/SQSTM1 in osteoclast signaling pathways.
McManus S, Roux S.
J Mol Signal. 2012 Jan 4;7:1. doi: 10.1186/1750-2187-7-1. PMID: 22216904

Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro.
McManus S, Chamoux E, Bisson M, Roux S.
Apoptosis. 2012 Feb;17(2):121-31. doi: 10.1007/s10495-011-0662-5. PMID: 21972115

BMP-9-induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment.
Leblanc E, Trensz F, Haroun S, Drouin G, Bergeron E, Penton CM, Montanaro F, Roux S, Faucheux N, Grenier G.
J Bone Miner Res. 2011 Jun;26(6):1166-77. doi: 10.1002/jbmr.311. PMID: 21611960

The RANK-RANKL-OPG axis in rheumatoid arthritis.
Roux S
Réflexions rhumatologiques 2011, 143:10-13.

The RANKL-RANK pathway: an update.
Roux S
Réflexions rhumatologiques2011, 143:4-9.

TRPV-5 mediates a receptor activator of NF-kappaB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption.
Chamoux E, Bisson M, Payet MD, Roux S.
J Biol Chem. 2010 Aug 13;285(33):25354-62. Epub 2010 Jun 11. PMID: 20547482 

Effect of functionalized polycaprolactone on the behaviour of murine preosteoblasts.
Drevelle O, Bergeron E, Senta H, Lauzon MA, Roux S, Grenier G, Faucheux N.
Biomaterials. 2010 Sep;31(25):6468-76. Epub 2010 Jun 9. PMID: 20542561 

RANK and RANKL expression in giant-cell tumour of bone.
Roux S, Mariette X.
Lancet Oncol. 2010 Jun;11(6):514. No abstract available. PMID: 20522381 

New treatment targets in osteoporosis.
Roux S.
Joint Bone Spine. 2010 May;77(3):222-8. Epub 2010 Apr 8. Review. PMID: 20381400  

Increased concentrations of prostaglandin D2 during post-fracture bone remodeling.
Gallant MA, Chamoux E, Bisson M, Wolsen C, Parent JL, Roux S, de Brum-Fernandes AJ.
J Rheumatol. 2010 Mar;37(3):644-9. Epub 2010 Jan 15. PMID: 20080921 

Gene expression profile in osteoclasts from patients with Paget's disease of bone.
Michou L, Chamoux E, Couture J, Morissette J, Brown JP, Roux S.
Bone. 2010 Mar;46(3):598-603. Epub 2009 Nov 17. PMID: 19925894 

New treatment targets in osteoporosis (Review).
Roux S.
Joint Bone Spine. 2010, 77:222-8.

The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts.
Chamoux E, Couture J, Bisson M, Morissette J, Brown JP, Roux S.
Mol Endocrinol. 2009 Oct;23(10):1668-80. Epub 2009 Jul 9. PMID: 19589897

Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.
Houde N, Chamoux E, Bisson M, Roux S.
J Biol Chem. 2009 Aug 28;284(35):23397-404. Epub 2009 Jul 1. PMID: 19574221

Cell responses to bone morphogenetic proteins and peptides derived from them: Biomedical applications and limitations.
Senta H, Park H, Bergeron E, Drevelle O, Fong D, Cabana F, Roux S, Grenier G, Faucheux N.
Cytokine & Growth Factor Reviews 2009, 20 : 213-222.

Osteoclast apoptosis in rheumatic diseases (Osteoporosis, Paget's Disease of Bone and Rheumatoid Arthritis).
Roux S, Brown JP.
Cur Rev Rheumatol 2009 5:98-110

Chapitres de livre / Articles didactiques

McManus S, Bissonnette L, Roux S.  Osteoclast biology in Paget's disease of bone (pp. 77-94). In: Osteoclasts: Morphology, Functions and Clinical Implications - A.J. Brown and J.S. Walker (Eds.), Nova Science Publishers, Hauppauge, NY, Oct. 2012.

Roux S, Philippin G, Vieillard MH. Malignant Bone Diseases (pp. 808-833). In J.W.J. Bijlsma (Ed.), J. Da Silva, E. Hachulla, M. Doherty, A. Cope & F. Lioté (Co-Eds.), Textbook on Rheumatic Diseases, BMJ Editions, London, 2012.

Leblanc E, Trensz F, Haroun S, Roux S, Faucheux N, Grenier G.  Heterotopic ossification after muscle damage: involvement of a new growth factor.
L'orthopode. 2010, 14(1):5-6. (Article didactique)

Roux S, Debiais F, Brown JP.  Malignant Bone Diseases (including new concepts and therapies as they apply to rheumatic diseases).  Education and training related to rheumatic diseases-EULAR (The European League Against Rheumatism) Compendium (2009).

Roux S. Manifestations ostéo-articulaires des leucémies aiguës, leucémies chroniques et des lymphomes. Chapitre 71-72-73. Rhumatologie. Collection Abrégés connaissances et pratique - COFER (Collège français des enseignants en rhumatologie) - Éditions Masson, Paris 2009.

Résumés

Beaulieu MC, Cabana F, Beaulieu M, Carrier N, Roux S, Boire G. "Improving Adherence Through Rapid Integrated Interdisciplinary Intervention After AFragility Fracture" Poster NAPCRG 41st Annual Meeting, Canada, Ontario, Ottawa, 2013-11-09

McManus S, Laberge G, Bisson M, Roux S. "PDK1/Akt pathway is involved inosteoclast signaling in Paget’s disease of bone" Abstract , J Bone Miner Res 2013, 29 (suppl 1). American Society for Bone and Mineral Research (ASBMR), United States, Maryland, Baltimore, 2013-10-04

Cabana F, Carrier N, Beaulieu MC, Beaulieu M, Roux S, Boire G. "WhichPatients with Ankle Fractures Are at Risk for Recurrent Fragility Fractures? Results from the OPTIMUS Initiative" Poster 2nd FFN Global Congress, Germany, Berlin, 2013-08-29

April PM, Cabana F, Beaulieu MC, Beaulieu M, Roux S, Boire G. "Up to half of first fragility fractures (FF), and a third of recurrent FF, occur in patients with low or moderate estimated FRAX® 10-year fracture risk: results from the OPTIMUS initiative" Abstract , Ann Rheum Dis 2013; 72 (suppl 2). European League Against Rheumatism (EULAR) Annual Congress, Spain, Madrid, 2013-06-13

Beaulieu MC, Roux S, Poirier N, Beaulieu M, Cabana F, Boire G. "Managementof fragility fractures: impact of the OPTIMUS initiative on family physicians". Abstract. J Bone Miner Res 2012, 27 (suppl 1), S109. American Society for Bone and Mineral Research (ASBMR), United States, Minnesota, Minneapolis, 2012-10-12

April PM, Poirier N, Roux S, Beaulieu MC, Beaulieu M, Cabana F, Boire G. Estimated FRAX® 10-year fracture risk at time of incident fracture and upon refracture: The OPTIMUS initiative. ASBMR (American Society for Bone and Mineral Research) Minneapolis 2012. J Bone Mir Res 2012 (suppl):S115.

Beaulieu MC, Roux S, Poirier N, Beaulieu M, Cabana F, Boire G. Management of fragility fractures: impact of the OPTIMUS initiative on family physicians. ASBMR Minneapolis 2012. J Bone Miner Res 2012 (suppl.) S109.

Boulay Jean S, McManus S, Roux S. (Role of the p62^P392L mutation in the activation of NFATc1 in pagetic osteoclasts. Journée scientifique FMSS, 41e Édition, Université de Sherbrooke, 2012.

de Brum-Fernandes AJ, Yue L, Roux S, McManus S. Prostaglandin D2 Induces Apoptosis of Human Osteoclasts Through the Activation of Akt and ERK Signaling Pathways.  ASBMR Minneapolis 2012. J. Bone Miner Res 2012 (suppl):S114.

Beaulieu MC, Cabana F, Beaulieu M, Roux S, Boire G. Manaement of fragility fractures: impact of the optimus initiative on family physicians. EULAR (The European League Against Rheumatism), Berlin, Germany, 2012. Ann Rheum Dis 2012; 71 (suppl 3):596.

Cabana F, Roux S, Beaulieu MC, Beaulieu M, Boire G. Incidence of subsequent fractures according to site of initial non-vertebral fractures and treatment status: the first 3 years of the OPTIMUS initiative.  EULAR, Berlin, 2012. Ann Rheum Dis 2012; 71(suppl 3):589.

Cabana F, Beaulieu M, Lambert D, Cote P, Vaillancourt M, Beaulieu M, Roux S, Boire G.
Incidence of Subsequent Fractures According to Age and Site of Initial Non-Vertebral Fractures: The First 3 Years of the OPTIMUS Initiative. ASBMR (Amercian Society for Bone and Mineral Research) San Diego 2011.
J Bone Miner Res 2011; 26(suppl 1): S484.

Chamoux E, Bisson M, Michou L, Brown JP, Roux S.  p62, PKCzeta and NF-kappaB Signaling in Human Osteoclasts: a Ling With Paget's Disease of Bone.  The American Sockiety for Bone and Minera Research (ASBMR), Toronto, ON, 2010. J Bone Miner Res 2010, 25(suppl 1):S185.

Fong D, Faucheux N, Roux S.  Characterization of the effects of Bone Morphogenetic Protein-9 on Osteoclast Physiology.  12th Quebec-Ontario Biotechnology Meeting, Montreal, QC, 2010.

Michou L, Chamoux E, Couture J, Morissette J, Brown JP, Roux S.  Identification of specific RNA isoforms of pagetic osteoclasts in Paget's disease of bone.  3rd Annual Canadian Human Genetics Conference, St-Sauveur, QC, 2010.

Fong D, Faucheux N, Roux S. Effect of BMP9 on osteoclast. 10e Édition de la Journée de la recherche de l'Université de Sherbrooke, Sherbrooke, QC, 2010.

Fong D, Faucheux N, Roux S. Effect of BMP9 on osteoclast. 78e Congrès de l'ACFAS : Association francophone pour le savoir, Montréal, QC, 2009.

McManus S, Roux S. TRAIL receptor modulation in an in vitro human osteoclast model. Symposium CORI (Clinical Oncology Research Initative), Orford, QC, 2009.

Fong D, Faucheux N, Roux S. Bone Morphogenetic Protein 9 Activates Smad Pathway and Supports Human Osteoclasts Survival in vitro in Presence of RANKL and M-CSF. American Society for Bone & Mineral Research, Denver, CO, 2009. J Bone Miner Res 2009,24 (Suppl 1). SU 229.

McManus S, Chamoux E, Roux S. Modulation of TRAIL receptors in a human osteoclast model in vitro. American Society for Bone & Mineral Research, Denver, CO, 2009. J Bone Miner Res2009, 24 (Suppl 1). SA 238.

Fong D, Faucheux N, Roux S. In vitroeffects of Bone Morphogenetic Protein 9 on human osteoclast physiology. 11th Ontario-Quebec CSChE (Canadian Society of Chemical Engineers) Biotechnology Meeting. Ottawa 2009.

Chamoux E., Bisson M., Payet D, Roux S. RANKL induces calcium channel activation in human osteoclasts. American Society for Bone & Mineral Research, Montreal, 2008. J Bone Miner Res 2008, 23 (suppll 1): S268.

Houde N, Chamoux E, Bisson M, Roux S. TGF-b1 induces human osteoclast apoptosis. American Society for Bone & Mineral Research, Montreal, 2008. J Bone Miner Res 2008, 23 (suppll 1): S261.

Gallant MA, Wollsen C, Chamoux E, Parent JL, Roux S, de Brum-Fernandes AJ. Prostaglandin D2 in human bone formation and remodelling. ASBMR, Honolulu, Hawaï, September 2007. J Bone Min Res 2007, 22 (suppl 1) S232.

Chamoux E, Couture J, Lemenchick B, Morissette J, Brown JP, Roux S. Effects of p62 mutations in human osteoclasts. ASBMR, Honolulu, Hawaï, September 2007. J Bone Min Res 2007, 22 (suppl 1) S220.

Couture J, Chamoux E, Morissette J, Brown JP, Roux S. Functional consequences of p62 mutations in osteoclasts in Paget's disease of bone. ASBMR, Honolulu, Hawaï, September 2007. J Bone Min Res 2007, 22 (suppl 1) S220.

Chamoux E, Couture J, Brown JP, Roux S. P62 signaling in osteoclasts and survival pathways. Paget's Symposium, Oxford, July 10-12, 2007. Osteoporosis International.

Chamoux E, Couture J, Brown JP, Roux S.  Expression and localisation of p62 (SQSTM1) in human osteoclasts.  J Bone Min Res 21 (Suppl. 1):S399, 2006.

Chamoux E, Leriger K, Aqil A, Roux S.  OPG decreases human osteoclast apoptosis by blocking TRAIL pathway.  J Bone Min Res 21 (Suppl. 1):S260, 2006.

Boire G, Cabana F, de Brum-Fernandes A, Liang P, Robindaine J, Hercelin D, Deschênes I, Roux S.  How much do rheumatologists make a difference?  Two strategies to improve treatment of osteoporosis following fragility hip fracture.  Ann Rheum Dis 64 (Suppl. 11):348, 2005.

Boire G, Cossette P, Daniel C, de Brum-Fernandes A, Hercelin D, Liang P, Ménard HA, Niyonsenga T, Roux S.  Fluctuations of anti-CCP antibodies and rheumatoid factor during follow-up of patients with recent-onset polyarthritis: correlations with clinical outcomes.  J Rheumatol 32 (Suppl.) 7:1400, 2005.  Ann Rheum Dis 64 (Suppl. 11):1174, 2005.

Boire G, Cabana F, Fernandes A, Liang P, Robindaine J, Hercelin D, Deschênes I, Roux S. Rheumatologists make a difference: 2 strategies to improve treatment of osteoporosis following fragility hip fracture. J Rheumatol 32 (Suppl.) 7:1401, 2005.